Herein, we report the results of an open-label, single-center phase II clinical trial evaluating the efficacy of azacitidine in the setting of MRD-triggered (decrease of CD34 + donor chimerism below ...

Please provide your email address to receive an email when new articles are posted on . The addition of azacitidine to venetoclax significantly improved response rates and OS among certain patients ...

Please provide your email address to receive an email when new articles are posted on . The regimen was particularly effective for patients who had not previously received hypomethylating agents, as ...

The investigational anti-CD47 monoclonal antibody magrolimab combined with azacitidine showed promising efficacy and was well tolerated in patients with untreated higher-risk myelodysplastic syndromes ...

ORLANDO, Florida — For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival — a new oral formulation of an old ...

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of. During a recent visit to the Georgia Cancer Center, CURE sat down for ...

The appraisal committee considered evidence submitted by Celgene and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response ...

A phase 3 trial evaluating ivosidenib plus azacitidine in adults with previously untreated IDH1-mutated AML showed that it met all endpoints. Positive results from a phase 3 trial evaluating ...

Review the side-effects of Azacitidine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

You have full access to this article via your institution. To the best of our knowledge, our two cases are the first reported cases that showed a very good response to 5-azacitidine in the setting of ...

NICE has today issued final guidance recommending azacitidine (Vidaza, Celgene) as a treatment option for people with myelodysplastic syndromes (MDS). Azacitidine has been recommended in line with its ...